



Universiteit
Leiden
The Netherlands

Living positive: eHealth for people with HIV and depressive symptoms

Luenen, S. van

Citation

Luenen, S. van. (2019, June 26). *Living positive: eHealth for people with HIV and depressive symptoms*. Retrieved from <https://hdl.handle.net/1887/74437>

Version: Not Applicable (or Unknown)

License: [Leiden University Non-exclusive license](#)

Downloaded from: <https://hdl.handle.net/1887/74437>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/74437> holds various files of this Leiden University dissertation.

Author: Luenen, S. van

Title: Living positive: eHealth for people with HIV and depressive symptoms

Issue Date: 2019-06-26



Chapter 4

An Internet-based self-help intervention for people with HIV and depressive symptoms: Study protocol for a randomized controlled trial

Published as:

Van Luenen, S., Kraaij, V., Spinhoven, P. & Garnefski, N. (2016). An Internet-based self-help intervention for people with HIV and depressive symptoms: study protocol for a randomized controlled trial. *Trials*, 17, 1-12. Doi: [10.1186/s13063-016-1292-6](https://doi.org/10.1186/s13063-016-1292-6).

Abstract

Background: Many people living with HIV suffer from depressive symptoms. In a previous pilot study, self-help cognitive behavioral therapy (in booklet format) was found to be effective in treating depressive symptoms in people with HIV. We developed an online self-help program in Dutch and English (based on the booklet) for people with HIV and depressive symptoms. Besides the main question regarding the effectiveness of the program aimed at lowering depressive symptoms, sub-questions will focus on the moderators of treatment success (for which patients is the program especially beneficial?) and the mechanisms of change underlying the treatment outcome (which mediators affect the outcome of treatment?). In this paper, the protocol of the study will be described.

Methods/design: The effectiveness of the program will be investigated by comparing the intervention group with a waiting list-control group in a randomized controlled design, by including a pretest and three post-tests. The self-help program contains four main components: activation, relaxation, changing maladaptive cognitions, and goal attainment. Participants with mild to moderate depressive symptoms will work on the program for six to ten weeks, during which a coach will provide motivational support by telephone once a week. Participants in the control condition will receive weekly minimal support from a coach for eight weeks, and after the second post-test, they can gain access to the self-help program. Depressive symptoms and possible mediators (e.g., activation, cognitive coping, self-efficacy, and goal adjustment) will be assessed by self-report three times during the intervention/waiting period and at the pretest and first post-test.

Discussion: The proposed study aims to evaluate the effectiveness of an online self-help intervention for people with HIV and depressive symptoms. If the intervention is shown to be effective, the program will be implemented.

Consequently, many patients with HIV could be reached, and their psychological care may be improved.

Trial registration: Netherlands Trial Register: NTR5407

Keywords: HIV, Depression, Internet, Self-help, Cognitive behavioral therapy, Coaching, Randomized controlled trial

Introduction

Currently, HIV is a chronic disease that requires the use of medication. Along with the physical problems that people living with HIV (PLWH) may experience (e.g., linked to the side effects of medication or comorbidities), psychological symptoms are also prevalent (1, 2). Specifically, depressive symptoms are often reported by PLWH. Many PLWH struggle, for example, with the daily use of medication and thinking about whom to tell about their HIV (3). This and more general life stressors may lead to depressive symptoms in PLWH. In turn, PLWH with depressive symptoms have a higher chance of non-adherence to their medication (4). This can result in more physical symptoms and illness. Therefore, the treatment of depressive symptoms in PLWH is important.

Various treatments are available for PLWH with depressive symptoms. Group and individual therapies exist, and many of these contain cognitive behavioral components (see review studies (5-9)). These treatments are effective in decreasing depressive symptoms and improving the quality of life in PLWH (2, 5, 7-9). Furthermore, beneficial effects were also found for medication adherence (6).

These group and individual therapies have some disadvantages. First, patients and therapists should meet in person during office hours for the treatment. Second, the costs of these treatments are high. Third, for HIV-specific programs, the stigma is a significant barrier to service delivery and utilization (10). A self-help program could be a way to overcome these disadvantages and barriers. The evidence base for low-intensity interventions has been growing in recent years, with high-quality trials supporting the effectiveness of self-help cognitive behavioral therapy (CBT) for depression (11-13).

A low-cost CBT self-help booklet for PLWH was developed based on prior research and a needs assessment (14-17). The self-help booklet contains three main components: relaxation, changing maladaptive cognitions, and goal attainment. The effectiveness of this booklet was tested in a pilot randomized controlled trial (RCT) (18). The results indicated that this intervention was effective in reducing the depressive symptoms in PLWH, compared to waiting list controls. However, in this RCT, 25% of the participants dropped out during the intervention phase. Elements should therefore be added to retain more PLWH in the program and to increase the effectiveness. In addition, several participants indicated they were worried that having the booklet in their home would disclose their HIV-positive status. They would have valued a less stigmatizing mode.

Therefore, the self-help booklet was converted into an Internet version. The online program contains eight lessons, which can be completed in six to ten weeks. An online program has a lower stigma, is easily accessible, can reach more people, and has lower long-term costs. Previous studies showed that online self-help therapy for depression in people with chronic illness was effective (19). In addition to being converted from a booklet into an Internet version, the program was expanded in three ways in the proposed study:

1. An activation component was added, in which participants will be stimulated to perform (small) activities (e.g., wake up on time). Activation is often used in CBT for depression as a first step (20).
2. Minimal coaching with motivational interviewing will be offered. A meta-analysis (12) showed a greater effectiveness of the Internet therapy when coaching was included, also when given in a minimal format. In addition, our recent studies including minimal coaching showed attrition rates between 10 and 15% (21).
3. Finally, in the current study, the online intervention will be available in Dutch and English to reach more PLWH in the Netherlands (and possibly in other countries in the future).

In 2014, the development of the online program was finalized, and we asked a focus group (four volunteers from the Dutch HIV Association) to evaluate the program. Thereafter, we adapted the program, and we conducted a pilot study with 20 PLWH with depressive symptoms (14 males; mean age = 48.65 years, *SD* = 10.86) to test the feasibility of the program. Participants were approached via advertisements on the website and in the magazine of the Dutch HIV Association and were representative of the Dutch HIV population. The results of the pilot study showed that the program was effective in this small group; depressive symptoms decreased from pre-test to post-test. Furthermore, participants thought the program was easy to use and helpful to them. These results encouraged us to execute a large study on the effectiveness of the online self-help program.

The aim of the present paper is to describe the study protocol. The proposed study is a randomized controlled trial; the online self-help program will be compared with a waiting list control condition. The study will include a pretest and three post-tests for the intervention condition (directly after the intervention and three and six months afterward) and a pretest and two post-tests (directly after the eight week waiting period and three months afterward) for the control condition. After the second post-test (five months after the pretest), the participants in the control group can also begin the program. Concluding, we will investigate the effectiveness of the online self-help program in decreasing depressive symptoms in the short and long term. In addition, the moderators (for which patients is the program especially beneficial?) and mediators (which mechanisms affect the outcome of treatment?) will be assessed.

Methods

Design

The study is a randomized controlled trial; participants will be randomly allocated to the intervention or the control group. Stratified randomization by treatment center and sex will be conducted.

Stratification by sex is conducted, as there will be more male participants in the study, and the allocation of approximately the same number of females to the intervention group as to the control group is preferred. In addition, stratification by treatment center is being conducted because the number of (included) patients will differ among the treatment centers. Approximately equal allocation to each of the groups also in the small treatment centers, is important. This will be realized by creating random number tables for each treatment center, divided by sex. Randomization will take place in blocks of 12 participants for each treatment center. Males and females will represent separate blocks, with six males and six females for each treatment center, of which half will be randomly allocated to the intervention group, and half will be allocated to the control group. Participants, coaches, and researchers cannot be blind for allocation to conditions. Participants will be allocated to one of the conditions after the pretest. The random number tables will be created by an independent researcher, and the allocation sequence will be concealed from the main researcher, who enrolls and informs participants.

The design consists of multiple measurements, one pretest, three post-tests (two in the control group), and three assessments during the intervention/waiting period. Figure 1 shows a flow chart of the study design, and the SPIRIT Checklist is presented in Additional file 1. The study is approved by the medical ethics committee of the Leiden University Medical Center (LUMC; nr. P14.091). Online informed consent will be obtained from all participants.

Participants

At least 200 participants who are PLWH with mild to moderate depressive symptoms will be included. Participants will be approached in 23 of the 27 HIV treatment centers throughout the Netherlands during their regular visits to the HIV nursing consultants and doctors. To be eligible to participate in the study, a participant must meet all of the following criteria: being HIV positive, exhibiting mild to moderate depressive symptoms (defined as Patient Health Questionnaire 9 (PHQ-9) (22) score > 4 and < 20), age 18 and older, having sufficient knowledge of the Dutch or English language, able to access the Internet, having an e-mail address, and available for the next eight weeks to work on the intervention.

An eligible participant who meets any of the following criteria will be excluded from participation in the study: being in the first half year following HIV diagnosis, having severe cognitive impairments (e.g., forgetfulness), exhibiting severe depressive symptoms (defined as PHQ-9 score of 20 or higher), experiencing suicidal ideation (indicated by a score > 1 on the suicide item of the PHQ-9), showing an absence of depressive symptoms (indicated by a PHQ-9 score of four or lower), undergoing treatment presently by a psychologist or psychiatrist, or on antidepressants for less than three months or has experienced a change of type or dose of antidepressants in the past three months.

In case of severe depressive symptoms (using the set criterion) and/or suicide ideation, patients will be referred to their general practitioner or the HIV treatment center.




Figure 1. Flow chart of study design

Sample size

A power analysis was performed (with the program Power Analysis and Sample Size Software: PASS; (23)) to determine the sample size needed to assess the long-term effect of the intervention on the primary outcome depressive symptoms. Based on a medium effect size of 0.50, which proved to be realistic according to the previous pilot RCT, and assuming an alpha of 0.05 and a power of 0.80, both groups should consist of 64 participants who complete the four measurements. This sample size is also large enough to detect moderate pre-defined two-way cross-product interactions, such as the interactions of group by sex. Taking into account a drop-out rate of 15% during working on the self-help program (based on our recent studies, which included coaching (21)), at least 150 patients should

be allocated to the two groups at baseline ($n = 75$ in each group). We will aim for at least 200 participants because dropout will also occur during the follow-up.

Procedure

HIV nursing consultants and doctors in the treatment centers will screen as many PLWH as possible for the level of depression at regular check-ups by means of the PHQ-2 (24). In some of the treatment centers, the Hospital Anxiety and Depression Scale (HADS (25)) will be used instead of the PHQ-2 because this scale was already in use in these centers. HIV treatment centers will receive information about the study and a guideline for the screening. A form will be used for the screening, and the forms will be sent to the researchers. Patients will be screened over approximately six months; most patients visit the HIV treatment center once every six months. If the PHQ-2 score is > 0 , patients may be referred to the researchers. Patients will receive written information about the study and permission will be asked to provide the researchers with their e-mail addresses and telephone numbers, so the researchers may contact the patients. The researchers will provide additional information to the patients and screen them more extensively with the PHQ-9. If the depression score is mild ($\text{PHQ-9} > 4$) to moderate ($\text{PHQ-9} < 20$), patients are eligible for the study and will be invited to participate. After giving online informed consent, participants will be asked for permission to inform their general practitioner and the HIV treatment center about participation in the study. Thereafter, all participants will complete the pretest via online questionnaires (T0). Next, participants will be randomly allocated to either the intervention or the control condition. At the start of the intervention, the personal coach will contact the participant by telephone in order to check and improve motivation by using the technique of motivational interviewing.

Subsequently, participants in the intervention group will follow the self-help program for six to ten weeks and receive support from a coach (see study conditions). They will be asked to fill out online questionnaires three times during the intervention, after they complete the program (T1, a maximum of ten weeks after T0), three months later (T2), and again three months later (T3). Participants who are allocated to the control condition will receive minimal support for eight weeks (for details see study conditions). They will also be asked to fill out the questionnaires, including the T2. After the T2 (which is completed approximately five months after T0), the participants will also receive the online intervention. Coaches will monitor the well-being of participants in both groups (see ethical precautions). We will raffle off gift cards and iPods among the participants who completed all questionnaires during the study.

Study conditions

Online self-help intervention

The self-help intervention is grounded in the theories of self-regulation and stress-coping, incorporating techniques of CBT and stress-management. The content of the program reflects four main components covered in eight lessons: activation, relaxation, changing maladaptive cognitions, and goal attainment. The program contains a combination of psycho-education, exercises, and assignments, all strengthened by motivation and support to increase the effectiveness and to minimize the attrition over time.

The intervention is offered through a secured website that contains the complete work program. Participants work on the intervention one to two hours a week for a period of six to ten weeks. The program starts with an introduction, and participants are asked to think of a small activity to perform (e.g., taking a short walk; lesson 1). They are stimulated to perform this activity in the following weeks and to expand this to other activities. Furthermore, participants will be instructed to do relaxation exercises and to continue these exercises in the coming weeks (lesson 2). Thereafter, participants learn to identify and change irrational cognitions (by challenging negative thoughts) and to evoke a strong and positive feeling when they experience negative feelings (lessons 3-5). Furthermore, participants are guided to formulate a new, realistic, concrete goal (such as quit smoking) and work on the stepwise attainment of this goal (lessons 6-7). Finally, the participant will work on a concluding and summarizing lesson (lesson 8). All participants will receive support from a coach during the intervention (see below).

Waiting list control condition

Participants randomized to the control group will be placed on a waiting list and will receive the intervention after T2. They will receive an initial phone call to explain the procedures (to minimize attrition). Participants will receive minimal support from a coach (see below).

Support from a coach

Participants in the intervention group will be allocated to a coach, who will provide motivation and support throughout the program. During the first telephone contact, the coach will introduce the program, motivate the participant, and address technical aspects. Once a week, a prescheduled telephone call of approximately 15 minutes will be arranged between the participant and the allocated coach. Coaching will be provided through queries about the participant's progress, motivational remarks, support in case problems are encountered, and encouragement to continue the program. Coaching will not include formal psychotherapy and will be provided until the participant completes

the program or for a maximum of ten weeks. If the participant is not finished with the program after ten weeks, the coaching will end, but the participant can continue the program.

Participants in the control group will also be allocated to a coach, who will provide minimal support over eight weeks. Participants will have a pre-scheduled weekly telephone call of approximately five minutes with the coach. The coach will address the well-being of the participant. Coaches will try to prevent participant dropout and monitor their depressive symptoms. When depressive symptoms or suicidal thoughts increase, the coach will act appropriately (see ethical precautions).

A protocol for coaching will be used, with guidelines available for the provision of support. Coaches will receive a short training to inform them about the study and the coaching procedures. After each telephone call, coaches will note the elements that were used during the call (e.g., motivation, support) to monitor treatment integrity. Coaches will be Master students in clinical psychology or individuals with a Master's degree in the field of psychology. The coaches will have completed clinical courses during their Master's degree program in which they learned communication skills, interview techniques, and treatment strategies. In addition, coaches will be selected in a personal interview on the basis of adequate communication skills for the support and motivation of participants. Coaches will be supervised by the researchers and a psychotherapist. Once every two weeks (every week during the first month of the study), the coaches and the main researcher will hold an intervision meeting. Coaches can discuss difficulties and questions with each other and the researcher. If a problem arises between intervision sessions, the coach may contact the researcher. The researcher and the coach can consult a psychotherapist if necessary.

Ethical precautions

Coaches will monitor the well-being of participants in both the intervention and control groups. Each week, they will ask how the participant is doing. When depressive symptoms worsen or when suicidal thoughts increase, the coach will discuss this with the participant. The coach can refer the participant to the general practitioner or the HIV treatment center, if necessary. The coach can discuss this with the researcher and the psychotherapist. When a participant is referred for more intensive treatment from a psychologist or psychiatrist, the participant may continue with the study. As this may influence the outcomes, the referral will be added as a covariate in the analysis.

Participants will complete questionnaires to assess depressive symptoms during the course of the study. When depressive symptoms of a participant increase, the researcher will notify the coach about this. The coach will discuss this increase of symptoms with the participant and will act appropriately. These guidelines are also described in the protocol for coaches.

Assessments

All assessments are self-reports and will be conducted online (except for the PHQ-2, which will be on paper for screening by the HIV nursing consultants and doctors and the PHQ-9, which will be used by the researchers for screening by telephone). Table 1 depicts all the assessment instruments that will be used in each stage of the study. The primary outcome is depression severity, as measured by the PHQ-9 (22) and the Center for Epidemiologic Studies Depression Scale (CES-D (26)). Secondary outcomes are physical tension, activation (Behavioral Activation for Depression Scale (BADs) (27)), cognitive reappraisal (Emotion Regulation Questionnaire (ERQ) (28)), cognitive coping (Cognitive Emotion Regulation Questionnaire (CERQ) (29)), depressive thoughts (Crandell Cognitions Inventory (CCI) (30)), behavioral coping (Behavioral Emotion Regulation Questionnaire (BERQ) Kraaij & Garnefski, unpublished questionnaire), coping self-efficacy (Kraaij & Garnefski, unpublished questionnaire), goal adjustment (Goal Disengagement and Reengagement Scale (31)), personal growth (Garnefski & Kraaij, unpublished questionnaire), symptoms of anxiety (Generalized Anxiety Disorder 7 (GAD-7) (32)), negative life events (Life Events Scale, (33)), motivation to start with the intervention, compliance, dropout and reasons for dropout, medical data, and user satisfaction.

As potential moderators of treatment outcome demographic variables (sex, age, education, and nationality), clinical and psychological characteristics (severity of depressive symptoms at baseline, anxiety symptoms at baseline, coping self-efficacy, physical health, HIV status, motivation, and alcohol and drug use) will be tested at first. Previous research indicated that some of these moderators (e.g., sex and baseline depression severity) might be important in online CBT for depression (34, 35). In addition, other possible moderators will be investigated exploratory.

The mediator variables and the dependent variable will be measured three times during the intervention/waiting period, at the pretest, and at the first post-test. The following mediator variables will be assessed in the study: activation (two items of the BADs), physical tension (two items), cognitive reappraisal (two items of the ERQ), cognitive coping (12 items of the CERQ), goal adjustment (two items of the Goal Disengagement and Reengagement Scale), symptoms of anxiety (PHQ-4 (36)), and coping self-efficacy (two items). The dependent variable in the mediational analysis is the depressive symptoms (PHQ-4). The questions (regarding, for example, symptoms and cognitions) that will be asked during the intervention/waiting period will refer to the last week. The assessments will be administered three times during the intervention/waiting period because, at these moments, we expect change in the mediating variables. The assessments are linked to the lessons of the self-help program for participants in the intervention group. At the first measurement, we expect a change in the behavioral activation; at the second measurement, we expect a change in the physical tension; at the third measurement, we expect a change in the cognitive reappraisal and cognitive coping; and at

the post-test, we expect a change in the goal adjustment. Coping self-efficacy and anxiety are expected to change over the entire course of the treatment.

Patient Health Questionnaire 9 (PHQ-9)

Depressive symptoms will be measured with the PHQ-9 at the pre- and post-tests (22). The questionnaire consists of nine items and includes the DSM-V criteria for a major depressive disorder. The items are rated on a four-point scale ranging from zero “not at all” to three “nearly every day,” e.g., “Over the last two weeks, how often have you been bothered by: little interest or pleasure in doing things?” Scores range from 0 to 27, and cutpoints of 5, 10, 15, and 20 represent mild, moderate, moderately severe, and severe levels of depressive symptoms. The PHQ-9 is sensitive to change, has good sensitivity and specificity for detecting depressive disorders, and has adequate psychometric properties (37). Furthermore, the questionnaire is often used with PLWH (38). This questionnaire will be used to screen participants on depressive symptoms and to measure change in depressive symptoms from baseline to the post-tests.

Center of Epidemiologic Studies Depression Scale (CES-D)

The CES-D (26) will be used to measure depressive symptoms during the past week. The questionnaire consists of 20 items, such as “During the past week: I felt sad.” Items are rated on a four-point scale ranging from zero “rarely or none of the time (less than 1 day)” to three “most or all of the time (5-7 days).” Total scores can range from 0 to 60, and the cut-off score for clinical depression is 16. The internal consistency, reliability, and convergent validity of the CES-D are adequate (26, 39), and sensitivity and specificity are high (40). Furthermore, the questionnaire is often used with PLWH (41). We will use this questionnaire to measure the change in depressive symptoms from the pretest to the post-tests.

Table 1. Overview of assessments during the study

Assessment	Screening HIV treatment centers (+/- 5 minutes)	Screening researchers (+/- 10 minutes)	T0: Pretest (+/- 25 minutes)	Three times during intervention / waiting period (+/- 10 minutes)	T1: post intervention / waiting period 6-10 weeks after T0 (+/- 20 minutes)	T2: 3-month follow-up (+/- 20 minutes)	T3: 6-month follow-up ^a (+/- 20 minutes)
PHQ-2 ^b or HADS ^c	X	-	-	-	-	-	-
PHQ-9 ^d	-	X	X	-	X	X	X
CES-D ^e	-	-	X	-	X	X	X
Demographics and other information	-	-	X	-	X	X	X
Physical tension questionnaire	-	-	X	X	X	X	X
BADS ^f	-	-	X	X	X	X	X
ERQ ^g	-	-	X	X	X	X	X
CERQ ^h	-	-	X	X	X	X	X
CCI ⁱ	-	-	X	-	X	X	X
Self-efficacy questionnaire	-	-	X	X	X	X	X
Goal disengagement and reengagement scale	-	-	X	X	X	X	X
BERQ ^j	-	-	X	-	X	X	X
Personal growth questionnaire	-	-	X	-	X	X	X
GAD-7 ^k	-	-	X	-	X	X	X
PHQ-4 ^l	-	-	-	X	-	-	-
Life Events Scale	-	-	X	-	X	X	X
Motivation	-	-	X	-	-	-	-
Compliance	-	-	-	X	X	X ^a	X
Dropout	-	-	-	X	X	X	X
Medical data	-	-	X	-	-	-	X

User satisfaction questionnaire

X

^a Not send to participants in the control group, ^b PHQ-2 = Patient Health Questionnaire 2, ^c HADS = Hospital Anxiety and Depression Scale, ^d PHQ-9 = Patient Health Questionnaire-9, ^e CES-D = Center of Epidemiologic Studies Depression Scale, ^f BADS = Behavioral Activation for Depression Scale, ^g ERQ = Emotion Regulation Questionnaire, ^h CERQ = Cognitive Emotion Regulation Questionnaire, ⁱ CCI = Crandell Cognitions Inventory, ^j BERQ = Behavioral Emotion Regulation Questionnaire, ^k GAD-7 = Generalized Anxiety Disorder 7, ^l PHQ-4 = Patient Health Questionnaire 4.

Demographic variables and other information

A self-designed questionnaire will be used to ask participants about sex, age, educational level, nationality, marital status, sexual orientation, social support, disclosure of HIV positive status, alcohol and drug use, previous depressive and anxiety episodes, treatment of psychological symptoms, and physical health. This information will be used to describe the demographic and clinical characteristics of the sample. In the follow-up assessments, questions will be asked about the use of medication for psychological problems and treatment received from a psychologist or a psychiatrist since the start of the study. The use of medication and treatment received will be added as covariates in the analysis.

Furthermore, participants will complete a self-designed questionnaire about information regarding the HIV infection. Questions include time since the HIV diagnosis, how the infection occurred, symptoms of the infection, cluster of differentiation 4 (CD4) cell count, viral load, use of antiretroviral therapy (ART), medication adherence, and side effects of the medication. This information will be used to describe the HIV status and use of ART by the sample.

Physical tension questionnaire

Physical tension will be measured with a self-designed ten item questionnaire. Questions include difficulty to relax, ways to relax, and symptoms of physical tension (e.g., trembling hands, tense neck and shoulder muscles, and increased heart rate). Items can be answered on a three-point scale (no, sometimes, and yes). Higher scores reflect less physical tension.

Behavioral Activation for Depression Scale (BADs)

The subscale activation of the BADs (27) will be used to measure activation during the past week. The subscale consists of seven items that will be measured on a seven-point scale ranging from zero "not at all" to six "completely," e.g., "I am content with the amount and types of things I did." Higher scores reflect greater levels of activation. The psychometric properties of the Dutch BADs are adequate (42).

Emotion Regulation Questionnaire (ERQ)

The reappraisal subscale of the ERQ (28) will be used to measure the cognitive reappraisal. The six items are rated on a scale ranging from one "strongly disagree" to seven "strongly agree," e.g., "When I want to feel less negative emotion, I change the way I'm thinking about the situation." Higher scores indicate that cognitive reappraisal is often used to regulate emotions. The convergent and discriminant validity of the ERQ are adequate (28).

Cognitive Emotion Regulation Questionnaire (CERQ)

The subscales rumination, catastrophizing, positive refocusing, refocus on planning, positive reappraisal, and putting into perspective of the CERQ (29) will be used to measure the use of these cognitive coping strategies when thinking about having HIV. The subscales consist of four items each, which will be rated on a five-point scale ranging from one “(almost) never,” to five “(almost) always.” Higher scores on a subscale indicate that this cognitive coping strategy is often used when thinking about having HIV. Examples of items include “I keep thinking about how terrible it is that I have HIV” (catastrophizing) and “I think about pleasant experiences” (positive refocusing). The psychometric properties of the CERQ are adequate (43).

Crandell Cognitions Inventory (CCI)

The hopelessness subscale of the CCI (30) will be used to measure black and white depressive thoughts. The subscale consists of seven items that are rated on a five-point scale ranging from one “(almost) never” to five “(almost) always,” e.g., “I’ll never feel good again.” Higher scores indicate a higher frequency of black and white depressive thinking. The reliability and validity of the CCI are good (30, 44).

Coping self-efficacy questionnaire

Self-efficacy to cope with having HIV will be measured with a self-designed eight-item questionnaire (Kraaij & Garnefski, unpublished questionnaire). The questionnaire is based on the Generalized Self-Efficacy Scale, which has a good reliability and validity (45). Items will be measured on a five-point scale ranging from one “totally disagree” to five “totally agree,” e.g., “I have the necessary skills to deal with having HIV.” High scores reflect more self-efficacy to cope with having HIV.

Goal Disengagement and Reengagement Scale

Goal adjustment will be measured with the Goal Disengagement and Reengagement Scale (31). We slightly adapted the scale so that questions will be asked regarding the disengagement and reengagement of goals that one has to stop pursuing because of having HIV. The scale consists of four items that measure goal disengagement (e.g., “If I have to stop pursuing an important goal in my life because I have HIV, it’s easy for me to reduce my effort toward the goal”) and six items that measure goal reengagement (e.g., “If I have to stop pursuing an important goal in my life because I have HIV, I start working on other new goals”). Items are measured on a five-point scale ranging from one “totally disagree” to five “totally agree.” Higher scores indicate more goal disengagement and reengagement. A question about new goals that have already been found will be added: “I have already found new

goals.” This last question will be handled separately, with higher scores indicating that more new goals were found.

Behavioral Emotion Regulation Questionnaire (BERQ)

The subscales seeking distraction, actively approaching, seeking social support, and withdrawal from the BERQ (Kraaij & Garnefski, unpublished questionnaire) will be used to measure the use of these behavioral strategies to cope with having HIV. Each subscale consists of four items that will be measured on a five-point scale ranging from one “never/hardly ever” to five “(nearly) always,” e.g., “I do other things to distract myself.” Higher scores on a subscale indicate that the strategy is often used to cope with having HIV. A previous study (Kraaij & Garnefski, in preparation) has shown a good reliability of this questionnaire.

Personal growth questionnaire

Personal growth due to having HIV will be measured with a self-designed five-item questionnaire (Garnefski & Kraaij, unpublished questionnaire). Items will be rated on a five-point scale ranging from one “not at all” to five “certainly,” e.g., “Because of having HIV I appreciate life more.” High scores indicate personal growth due to having HIV. In a previous study, the reliability of this questionnaire was adequate (15).

Generalized Anxiety Disorder 7 (GAD-7)

The severity of symptoms of anxiety will be investigated with the GAD-7 (32). The questionnaire consists of seven items that are rated on a four-point scale ranging from zero “not at all” to three “nearly every day,” e.g., “Over the last two weeks, how often have you been bothered by: feeling nervous, anxious or on edge.” Higher scores indicate more anxiety symptoms. The psychometric properties of the GAD-7 are adequate, and the scale also may be used as a screener for panic, social anxiety, and post-traumatic stress disorder (37).

Patient Health Questionnaire 2 and Patient Health Questionnaire 4 (PHQ-2 and PHQ-4)

The PHQ-4 (36) will be used to assess depressive and anxiety symptoms during the intervention or waiting period (for the mediational analysis). It consists of the first two questions of the PHQ-9 and the first two questions of the GAD-7. Items are rated on a four-point scale ranging from zero “not at all” to three “nearly every day.” Higher scores indicate more pathology. The internal reliability, construct validity, and factorial validity are adequate (36). The PHQ-2 (24) consists of the first two questions of the PHQ-9 and will be used by the HIV treatment centers to screen for depressive symptoms.

Hospital Anxiety and Depression Scale (HADS)

The HADS (25) will be used by some of the HIV treatment centers to screen for depressive symptoms. The HADS consists of an anxiety and a depression subscale, and each subscale consists of seven questions, e.g., “I still enjoy the things I used to enjoy.” Items are rated on a four-point scale, and the response categories are different for each question. Higher scores indicate more anxiety and depressive symptoms. The HADS is widely used and is a reliable and valid questionnaire to screen for anxiety and depressive symptoms (25, 46).

Life Events Scale

Life events will be assessed with the Life Events Scale (33). The scale consists of 17 negative life events (e.g., divorce of parents), and participants indicate if they have not experienced the life event, experienced it longer than one year ago, or experienced it last year. For each of the two periods, a total score of negative life events will be calculated.

Motivation to start with the intervention

Three questions will be used to measure the motivation to start the intervention. Two questions will be asked regarding the expected usefulness of the intervention, and one question about the motivation to start with the intervention. Questions will be answered on a five-point scale, and the scores on the items will be summed.

Compliance

Two measures of program adherence will be used in this study. During the intervention, program adherence will be measured three times by asking participants whether they read the information on the website and performed the exercises. Furthermore, we will monitor whether the participant calls with the coach. These two measures will be handled separately.

Dropout and reasons for dropout

Two types of dropout will be investigated three times during the intervention and at T1, T2, and T3. We will register the participants who stopped using the intervention and the participants who did not complete the questionnaires. We will remind participants to fill in the questionnaires. When they drop out, we will ask them why they do not wish to participate anymore to investigate the reasons for dropout. We will examine the difference in dropout between groups and differences between participants who completed and stopped using the intervention.

Medical data

Medical data will be obtained from the Athena/SHM Cohort Study after consent from the participant. The ATHENA Cohort Study is maintained by Stichting HIV Monitoring, which is supported by the Dutch Ministry of Health via the National Institute for Public Health and Environment (RIVM). The data that will be used include the time since HIV diagnosis, medication use, CD4 cell count, and viral load.

User satisfaction questionnaire

At T1, we will ask participants about their satisfaction with the self-help program and the coach with a self-designed questionnaire. The questionnaire consists of 31 items to evaluate the intervention, for example, the components of the self-help program and the support from the coach. Open-ended and closed-ended questions will be used in the questionnaire. The questions for participants in the control group will concern the support from the coach (13 questions). The answers to these questions will be used to adjust the self-help program before implementing it.

Statistical analyses

A two-tailed alpha of 0.05 will be used for significance testing. All analyses will be based on an intention-to-treat (ITT) analysis, which includes all participants who were randomized to one of the groups at the beginning of the study (47). Baseline differences between conditions will be investigated with chi-square tests for categorical variables and ANOVAs for continuous variables.

To examine the effect of condition on the depressive symptoms at the post-tests, longitudinal multilevel regression analysis (LMRA) will be conducted (48). A two-level model will be studied: time at level 1 and participants at level 2. The variable time will have four categories indicating the four time points (T0–T3). The baseline (T0) will be used as reference category. The independent variable is condition, the dependent variable is the score on the PHQ-9 or the CES-D, and several covariates will be included in the model (e.g., sex and age). Multiple imputation for missing data is not necessary in LMRA because it can include participants with missing data on one or more time points (48). The existence of an effect of HIV treatment center will be investigated exploratory.

Furthermore, Cohen's *d* will be calculated to indicate within- and between-group effect sizes (49). In addition, clinically important differences for individual change in depressive symptoms will be examined. Change scores of five or more from the pretest to the post-tests will be considered as clinically important differences for the PHQ-9 (50).

With regard to all secondary outcomes, we will study the pre-treatment versus post-treatment changes by using the analyses described above for the PHQ-9 and the CES-D. To examine moderators of the treatment outcome, LMRA will be conducted. Potential moderators will be entered individually. Interaction effects will be investigated (e.g., time x condition x moderator). A limited number of cross-

product interactions will be examined, and we will correct for multiple testing. Furthermore, the QUINT (Qualitative Interaction Trees (51) method will be used to identify subgroups for which the intervention is most effective, by exploratory investigation of the multiple moderators.

Mediation will be tested by examining the indirect effect of the independent variable (condition) on the dependent variable (depressive symptoms) through the proposed mediators. Mediation analysis will be conducted by using latent difference score models, which are recommended with repeated measurements and multiple mediators (52). These models focus on intra-individual change and individual differences in that change.

Discussion

In the proposed study, we will investigate the effectiveness of an online self-help intervention for PLWH with depressive symptoms in a randomized controlled trial. Additionally, moderators and mediators of the treatment outcome will be assessed. This study has some strengths and limitations that will be discussed in the following section. First, a strength of this study is that the self-help program is online, so many people can be reached. Only PLWH without Internet or an e-mail address cannot participate, but most people in The Netherlands have access to the Internet. Second, participants can work on the program when and where they want and at their own pace. Third, the content of the program is based on prior research and a needs assessment among PLWH (14-18); that is, the program is designed especially for PLWH. Fourth, moderators of the treatment outcome will be studied; we will investigate for whom the program is especially beneficial. Investigations of the effect of personal characteristics on the treatment outcome are useful, so patients could receive the treatment that is most likely to decrease their depressive symptoms. Fifth, mediators of the treatment outcome will be assessed; the mechanisms of change of the intervention will be studied. Knowing more about exactly how the invention works is important. Knowing what is effective would allow the adaptation of the treatment to make it more efficient (53). Sixth, the support participants receive from the coach is also a strength in this study. The coach will motivate participants to continue with the program, and this will probably decrease the dropout. Lastly, most HIV treatment centers in the Netherlands agreed to screen patients for the study. This means that we will have PLWH from across the country participating in the study.

Furthermore, some limitations are present in the study. Patients with severe depressive symptoms and/or suicidal ideation will be excluded from the study. We argue that these patients should be closely monitored by a therapist. We expect that these patients would benefit from the self-help program, as has also been found in previous research (54), but more intense treatment is desirable for these patients. In addition, the follow-up period of participants in the control group is

only three months (they may start with the intervention after the three month follow-up), while this period is six months for the participants in the intervention group. However, we argue that it is not ethical to let people in the control group wait for approximately eight months before providing the intervention (eight weeks plus six months of follow-up). Therefore, the intervention will be offered to the control group after the second post-test. The last limitation concerns the screening of participants for depressive symptoms. We will use a questionnaire with nine items to measure depressive symptoms in PLWH. One could argue that a diagnostic interview will screen depressive symptoms more extensively and allow the identification of a possible depressive disorder. However, this approach would be time consuming, and the PHQ-9 is a reliable and valid measure of severity of depressive symptoms (37). Furthermore, the program is designed for people with mild to moderate depressive symptoms, so a diagnosis of depression is not an inclusion criterion for participation in the study.

To conclude, in the proposed study, we will evaluate an online self-help program for PLWH with depressive symptoms. Since depressive symptoms exist frequently in PLWH, low-cost and low-stigmatizing interventions are needed for these individuals. The proposed study offers an online self-help program that complies with this request. If the self-help program proves to be effective in the proposed study, implementation of the website will be done in cooperation with the Dutch patient organization (HIV Vereniging Nederland) and HIV treatment centers. Furthermore, the program may be implemented in other countries as well.

Acknowledgements

The proposed study is supported by the Aidsfonds (file number 2013027). We thank Elise Dusseldorp for her advice on the statistical analysis section. The HIV treatment centers will screen people with HIV on depressive symptoms and deliver data for the Athena/SHM Cohort Study. We thank the following nursing consultants and doctors for their efforts and collaboration:

Academic Medical Centre of the University of Amsterdam, Amsterdam. HIV treating physicians: JM Prins, JTM van der Meer, FWMN Wit, MH Godfried, P Reiss, T van der Poll, FJB Nellen, SE Geerlings, M van Vugt, WJ Wiersinga, M van der Valk, A Goorhuis, and JW Hovius. HIV nurse consultants: J van Eden, A Henderiks, AMH van Hes, M Mutschelknauss, HE Nobel, and FJJ Pijnappel.

Admiraal De Ruyter Ziekenhuis, Goes. HIV treating physicians: M van den Berge and A Stegeman. HIV nurse consultants: S Baas and L Hage.

Flevoziekenhuis, Almere. HIV treating physician: J Branger. HIV nurse consultants: CJHM Duijf-van de Ven and FA van Truijen-Oud.

Haga Ziekenhuis, Den Haag. HIV treating physicians: EF Schippers and C van Nieuwkoop. HIV nurse consultants: JM van IJperen and J Geilings.

HIV Focus Centrum (DC Klinieken), Amsterdam. HIV treating physician: A van Eeden. HIV nurse consultants: W Brokking, M Groot, and LJM Elsenburg.

Isala, Zwolle. HIV treating physicians: PHP Groeneveld and JW Bouwhuis. HIV nurse consultants: JF van den Berg and AGW van Hulzen.

Kennemer Gasthuis, Haarlem. HIV treating physicians: SFL van Lelyveld and R Soetekouw. HIV nurse consultants: N. Hulshoff, LMM van der Pijlt, M Schoemaker, and JM van der Swaluw.

Leids Universitair Medisch Centrum, Leiden. HIV treating physicians: FP Kroon, MGJ de Boer, H Jolink, and AM Vollaard. HIV nurse consultants: W Dorama, C Moons, and N van Holten.

Maasstad Ziekenhuis, Rotterdam. HIV treating physicians: JG den Hollander and K Pogany. HIV nurse consultants: M Kastelijns, JV Smit, E Smit, and D Struik.

MC Zuiderzee, Lelystad. HIV treating physicians: S Weijer and R El Moussaoui. HIV nurse consultant: AS Cents-Bosma.

Medisch Centrum Alkmaar, Alkmaar. HIV treating physicians: W Kortmann and G van Twillert. HIV nurse consultants: D Pronk and FA van Truijen-Oud.

Medisch Centrum Haaglanden, Den Haag. HIV treating physicians: EMS Leyten and LBS Gelinck. HIV nurse consultants: A van Hartingsveld, C Meerkerk, and GS Wildenbeest.

Medisch Centrum Leeuwarden, Leeuwarden. HIV treating physicians: MGA van Vonderen, DPF van Houte, and LM Kampschreur. HIV nurse consultants: K Dijkstra and S Faber.

Medisch Spectrum Twente, Enschede. HIV treating physicians: GJ Kootstra and CE Delsing. HIV nurse consultants: M van der Burg-van der Plas and H Heins.

Onze Lieve Vrouwe Gasthuis, Amsterdam. HIV treating physicians: K Brinkman, PHJ Frissen, WL Blok, WEM Schouten, and GEL van den Berk. HIV nurse consultants: CJ Brouwer, GF Geerders, K Hoeksema, MJ Kleene, IB van der Meché, AJM Toonen, and S Wijnands.

Radboud UMC, Nijmegen. HIV treating physicians: PP Koopmans, M Keuter, AJAM van der Ven, HJM ter Hofstede, ASM Dofferhoff, and R van Crevel. HIV nurse consultants: M Albers, MEW Bosch, KJT Grintjes-Huisman, and BJ Zomer.

Rijnstate, Arnhem. HIV treating physicians: C Richter, JP van der Berg, and EH Gisolf. HIV nurse consultants: G ter Beest, PHM van Bentum, and N Langebeek.

Slotervaartziekenhuis, Amsterdam. HIV treating physicians: JW Mulder, SME Vrouwenraets, and FN Lauw. HIV nurse consultants: MC van Broekhuizen, H Paap, and DJ Vlasblom.

Stichting Medisch Centrum Jan van Goyen, Amsterdam. HIV treating physician: DWM Verhagen. HIV nurse consultants: MC van Broekhuizen and H Paap.

St. Elisabeth Ziekenhuis, Tilburg. HIV treating physicians: MEE van Kasteren and AE Brouwer. HIV nurse consultants: BAFM de Kruijf-van de Wiel, MHJ Kuipers-Jansen, and BJM van der Ven.

Universitair Medisch Centrum Groningen, Groningen. HIV treating physicians: WFW Bierman, EH Scholvinck, S van Assen, KR Wilting, and Y Stienstra. HIV nurse consultants: H de Groot-de Jonge, PA van der Meulen, DA de Weerd, and J Ludwig.

Universitair Medisch Centrum Utrecht, Utrecht. HIV treating physicians: AIM Hoepelman, MME Schneider, T Mudrikova, PM Ellerbroek, JJ Oosterheert, JE Arends, RE Barth, and MWM Wassenberg. HIV nurse consultants: DHM van Elst-Laurijsen, EEB van Oers-Hazelzet, JC Patist, and SCJM Vervoort.

VU Medisch Centrum, Amsterdam. HIV treating physicians: EJG Peters, MA van Agtmael, M Bomers, and J de Vocht. HIV nurse consultants: M. Heitmuller and L. Laan.

Appendix

Appendix 1. SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents^a

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
	2b	All items from the World Health Organization Trial Registration Data Set	-
Protocol version	3	Date and version identifier	-
Funding	4	Sources and types of financial, material, and other support	25-27
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1,25
	5b	Name and contact information for the trial sponsor	-
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	-
Introduction			
Background rationale	and 6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4-6
	6b	Explanation for choice of comparators	10-12

Objectives	7	Specific objectives or hypotheses	6
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	6, 7
Methods: Participants, interventions, and outcomes			
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	7-10
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	7-9, 12
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	10-12
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	13
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	11, 12, 20
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	13
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	13-21
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	8
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	9

7, 9

15 Strategies for achieving adequate participant enrolment to reach target sample size

Methods: Assignment of interventions (for controlled trials)

Allocation:

16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. 6, 7

To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions

16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), - describing any steps to conceal the sequence until interventions are assigned

16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions 6, 7

17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how 7

17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention - during the trial

Methods: Data collection, management, and analysis

18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol 13-21

18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols 20, 21

Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	21-22
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	21-22
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	21-22
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	21-22
Methods: Monitoring			
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	
Ethics and dissemination			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	7
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	

Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	7, 10
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	21
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	-
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	25
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	-
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	13
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	-
	31b	Authorship eligibility guidelines and any intended use of professional writers	-
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	-
Appendices			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	-
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	-

^a It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" license.

References

1. Cruess DG, Evans DL, Repetto MJ, Gettes D, Douglas SD, Petitto JM. Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease. *Biol Psychiatry*. 2003;54(3):307-16.
2. Sherr L, Clucas C, Harding R, Sibley E, Catalan J. HIV and depression--a systematic review of interventions. *Psychol Health Med*. 2011;16(5):493-527.
3. Bravo P, Edwards A, Rollnick S, Elwyn G. Tough Decisions Faced by People Living with HIV: A Literature Review of Psychosocial Problems. *AIDS Rev*. 2010;12(2):76-88.
4. Gonzalez JS, Batchelder AW, C P, Safren SA. Depression and HIV/AIDS treatment nonadherence: A review and meta-analysis. *J Acquir Immune Defic Syndr*. 2011;58:181-7.
5. Brown JL, Venable PA. Cognitive-behavioral stress management interventions for persons living with HIV: a review and critique of the literature. *Ann Behav Med*. 2008;35(1):26-40.
6. Carrico AW, Antoni MH. Effects of psychological interventions on neuroendocrine hormone regulation and immune status in HIV-positive persons: A review of randomized controlled trials. *Psychosom Med*. 2008;70(5):575-84.
7. Crepaz N, Passin WF, Herbst JH, Rama SM, Malow RM, Purcell DW, et al. Meta-analysis of cognitive-behavioral interventions on HIV-positive persons' mental health and immune functioning. *Health Psychol*. 2008;27(1):4-14.
8. Scott-Sheldon LAJ, Kalichman SC, Carey MP, Fielder RL. Stress management interventions for HIV+ adults: A meta-analysis of Randomized controlled trials, 1989 to 2006. *Health Psychol*. 2008;27(2):129-39.
9. Spies G, Asmal L, Seedat S. Cognitive-behavioural interventions for mood and anxiety disorders in HIV: a systematic review. *J Affect Disord*. 2013;150(2):171-80.
10. Swendeman D, Ingram BL, Rotheram-Borus MJ. Common elements in self-management of HIV and other chronic illnesses: an integrative framework. *Aids Care-Psychological and Socio-Medical Aspects of Aids/Hiv*. 2009;21(10):1321-34.
11. Cuijpers P, Donker T, van Straten A, Li J, Andersson G. Is guided self-help as effective as face-to-face psychotherapy for depression and anxiety disorders? A systematic review and meta-analysis of comparative outcome studies. *Psychol Med*. 2010;40(12):1943-57.
12. Gellatly J, Bower P, Hennessy S, Richards D, Gilbody S, Lovell K. What makes self-help interventions effective in the management of depressive symptoms? Meta-analysis and meta-regression. *Psychol Med*. 2007;37(9):1217-28.
13. Williams C, Martinez R. Increasing Access to CBT: Stepped Care and CBT Self-Help Models in Practice. *Behav Cogn Psychother*. 2008;36(06):675.
14. Garnefski N, Kraaij V, Schroevers MJ. *Leven met HIV: zelfhulpboek voor het omgaan met HIV [Living with HIV: Self-help book for coping with HIV]*: Drukkerij Raddraaier, Amsterdam; 2010.
15. Kraaij V, Garnefski N, Schroevers MJ, van der Veek SM, Witlox R, Maes S. Cognitive coping, goal self-efficacy and personal growth in HIV-infected men who have sex with men. *Patient Educ Couns*. 2008;72(2):301-4.
16. Kraaij V, van der Veek SM, Garnefski N, Schroevers M, Witlox R, Maes S. Coping, goal adjustment, and psychological well-being in HIV-infected men who have sex with men. *AIDS Patient Care STDS*. 2008;22(5):395-402.
17. van der Veek SM, Kraaij V, Van Koppen W, Garnefski N, Joekes K. Goal disturbance, cognitive coping and psychological distress in HIV-infected persons. *J Health Psychol*. 2007;12(2):225-30.
18. Kraaij V, van Emmerik A, Garnefski N, Schroevers MJ, Lo-Fo-Wong D, van Empelen P, et al. Effects of a cognitive behavioral self-help program and a computerized structured writing intervention on depressed mood for HIV-infected people: a pilot randomized controlled trial. *Patient Educ Couns*. 2010;80(2):200-4.
19. van Beugen S, Ferwerda M, Hoeve D, Rovers MM, Spillekom-van Koulik S, van Middendorp H, et al. Internet-Based Cognitive Behavioral Therapy for Patients With Chronic Somatic Conditions: A Meta-Analytic Review. *J Med Internet Res*. 2014;16(3):e88.
20. Clarke G, Debar L, Lynch F, Powell J, Gale J, O'Connor E, et al. A Randomized effectiveness trial of brief cognitive-behavioral therapy for depressed adolescents receiving antidepressant medication. *J Am Acad Child Adolesc Psychiatry*. 2005;44(9):888-98.
21. Garnefski N, Kraaij V, Benoist M, Bout Z, Karels E, Smit A. Effect of a Cognitive Behavioral Self-Help Intervention on Depression, Anxiety, and Coping Self-Efficacy in People With Rheumatic Disease. *Arthritis Care Res (Hoboken)*. 2013;65(7):1077-84.
22. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9 - Validity of a brief depression severity measure. *J Gen Intern Med*. 2001;16(9):606-13.
23. Hintze J. NCSS and PASS (number cruncher statistical systems). Kaysville, Utah; 2004. Available from: www.NCSS.com.
24. Kroenke K, Spitzer RL, Williams JBW. The Patient Health Questionnaire-2 - Validity of a two-item depression screener. *Med Care*. 2003;41(11):1284-92.
25. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand*. 1983;67(6):361-70.

26. Radloff LS. The CES-D scale a self-report depression scale for research in the general population. *Appl Psychol Meas.* 1977;1(3):385-401.
27. Kanter JW, Mulick PS, Busch AM, Berlin KS, Martell CR. The Behavioral Activation for Depression Scale (BADs): Psychometric Properties and Factor Structure. *Journal of Psychopathology and Behavioral Assessment.* 2007;29(3):191-202.
28. Gross JJ, John OP. Individual differences in two emotion regulation processes: Implications for affect, relationships, and well-being. *J Pers Soc Psychol.* 2003;85(2):348-62.
29. Garnefski N, Kraaij V, Spinhoven P. Negative life events, cognitive emotion regulation and emotional problems. *Pers Individ Dif.* 2001;30(8):1311-27.
30. Crandell CJ, Chambless DL. The validation of an inventory for measuring depressive thoughts - The Crandell Cognitions Inventory. *Behav Res Ther.* 1986;24(4):403-11.
31. Wrosch C, Scheier MF, Miller GE, Schulz R, Carver CS. Adaptive self-regulation of unattainable goals: goal disengagement, goal reengagement, and subjective well-being. *Pers Soc Psychol Bull.* 2003;29(12):1494-508.
32. Spitzer RL, Kroenke K, Williams JBW, Lowe B. A brief measure for assessing generalized anxiety disorder - The GAD-7. *Arch Intern Med.* 2006;166(10):1092-7.
33. Garnefski N, Kraaij V. Life Events Scale Leiden University 2001. Available from: www.cerq.leidenuniv.nl.
34. Donker T, Batterham PJ, Warmerdam L, Bennett K, Bennett A, Cuijpers P, et al. Predictors and moderators of response to internet-delivered Interpersonal Psychotherapy and Cognitive Behavior Therapy for depression. *J Affect Disord.* 2013;151(1):343-51.
35. Warmerdam L, Van Straten A, Twisk J, Cuijpers P. Predicting outcome of Internet-based treatment for depressive symptoms. *Psychother Res.* 2013;23(5):559-67.
36. Kroenke K, Spitzer RL, Williams JBW, Löwe B. An Ultra-Brief Screening Scale for Anxiety and Depression: The PHQ-4. *Psychosomatics.* 2009;50(6):613-21.
37. Kroenke K, Spitzer RL, Williams JB, Lowe B. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. *Gen Hosp Psychiatry.* 2010;32(4):345-59.
38. Relf MV, Eisbach S, Okine KN, Ward T. Evidence-based clinical practice guidelines for managing depression in persons living with HIV. *J Assoc Nurses AIDS Care.* 2013;24(1 Suppl):S15-28.
39. Thombs BD, Hudson M, Schieir O, Taillefer SS, Baron M, Canadian Scleroderma Rese G. Reliability and validity of the Center for Epidemiologic Studies Depression Scale in patients with systemic sclerosis. *Arthritis & Rheumatism-Arthritis Care & Research.* 2008;59(3):438-43.
40. Tsai AC. Reliability and Validity of Depression Assessment Among Persons With HIV in Sub-Saharan Africa: Systematic Review and Meta-analysis. *Jaids-Journal of Acquired Immune Deficiency Syndromes.* 2014;66(5):503-11.
41. Simoni JM, Safren SA, Manhart LE, Lyda K, Grossman CI, Rao D, et al. Challenges in addressing depression in HIV research: assessment, cultural context, and methods. *AIDS Behav.* 2011;15(2):376-88.
42. Raes F, Hoes D, Van Gucht D, Kanter JW, Hermans D. The Dutch version of the Behavioral Activation for Depression Scale (BADs): psychometric properties and factor structure. *J Behav Ther Exp Psychiatry.* 2010;41(3):246-50.
43. Garnefski N, Kraaij V. The Cognitive Emotion Regulation Questionnaire - Psychometric features and prospective relationships with depression and anxiety in adults. *Eur J Psychol Assess.* 2007;23(3):141-9.
44. Glass CR, Arnkoff DB. Questionnaire methods of cognitive self-statement assessment. *J Consult Clin Psychol.* 1997;65(6):911-27.
45. Schwarzer R, Jerusalem M. Generalized Self-Efficacy Scale. In: Weinman J, Wright S, Johnston M, editors. *Measures in Health Psychology: a user's portfolio. Causal and control beliefs.* Windsor, UK: NFER-NELSON; 1995.
46. Spinhoven PH, Ormel J, Sloekers PPA, Kempen GJIM, Speckens AEM, Hemert AMV. A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. *Psychol Med.* 1997;27(2):363-70.
47. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. *Br Med J.* 1999;319(7211):670-+.
48. Stoel RD, van Den Wittenboer G, Hox J. Analyzing longitudinal data using multilevel regression and latent growth curve analysis. *Metodologia de las Ciencias del Comportamiento.* 2003;5(1):21-42.
49. Cohen J. A power primer. *Psychol Bull.* 1992;112(1):155-9.
50. Lowe B, Unutzer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment outcomes with the patient health questionnaire-9. *Med Care.* 2004;42(12):1194-201.
51. Dusseldorp E, Doove L, Van Mechelen I. Quint: An R package for identification of subgroups of clients who differ in which treatment alternative is best for them. *Behav Res Methods.* 2015;48(2):650-63.
52. Selig JP, Preacher KJ. Mediation Models for Longitudinal Data in Developmental Research. *Research in Human Development.* 2009;6(2-3):144-64.
53. Kazdin AE. Mediators and mechanisms of change in psychotherapy research. *Annu Rev Clin Psychol.* 2007;3:1-27.

54. van Straten A, Cuijpers P, Smits N. Effectiveness of a web-based self-help intervention for symptoms of depression, anxiety, and stress: randomized controlled trial. *J Med Internet Res*. 2008;10(1):e7.

